DE69500618D1 - Oligonukleotide mit wirkung gegen das respiratorische synzytial virus - Google Patents
Oligonukleotide mit wirkung gegen das respiratorische synzytial virusInfo
- Publication number
- DE69500618D1 DE69500618D1 DE69500618T DE69500618T DE69500618D1 DE 69500618 D1 DE69500618 D1 DE 69500618D1 DE 69500618 T DE69500618 T DE 69500618T DE 69500618 T DE69500618 T DE 69500618T DE 69500618 D1 DE69500618 D1 DE 69500618D1
- Authority
- DE
- Germany
- Prior art keywords
- oligonucleotides
- respiratory syncytial
- syncytial virus
- effect against
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 4
- 241000725643 Respiratory syncytial virus Species 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19950394A | 1994-02-18 | 1994-02-18 | |
| PCT/US1995/002080 WO1995022553A1 (en) | 1994-02-18 | 1995-02-17 | Oligonucleotides with anti-respiratory syncytial virus activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69500618D1 true DE69500618D1 (de) | 1997-10-02 |
Family
ID=22737804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69500618T Expired - Lifetime DE69500618D1 (de) | 1994-02-18 | 1995-02-17 | Oligonukleotide mit wirkung gegen das respiratorische synzytial virus |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0745090B1 (de) |
| JP (1) | JPH09509181A (de) |
| AT (1) | ATE157370T1 (de) |
| AU (1) | AU1878895A (de) |
| CA (1) | CA2181546A1 (de) |
| DE (1) | DE69500618D1 (de) |
| WO (1) | WO1995022553A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997014792A2 (en) * | 1995-10-17 | 1997-04-24 | Hybridon, Inc. | Oligonucleotides with anti-respiratory syncytial virus activity |
| EP1007655A4 (de) * | 1996-02-15 | 2000-06-14 | Nat Inst Health | Aktivatoren der rnase l und antisense-oligonukleotide zur behandlung von rsv-infektionen |
| US6214805B1 (en) * | 1996-02-15 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
| US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5831069A (en) * | 1997-03-04 | 1998-11-03 | South Alabama Medical Science Foundation | Antisense oligonucleotides against nonstructural proteins NS1 and NS2 of respiratory syncytial virus and uses thereof |
| WO2003062258A1 (en) * | 2002-01-22 | 2003-07-31 | The Cleveland Clinic Foundation | Rnase l activator-antisense complexes |
| EP3415625A1 (de) | 2002-02-01 | 2018-12-19 | Life Technologies Corporation | Doppelsträngige oligonukleotide |
| CA2715289C (en) | 2008-02-11 | 2019-12-24 | Rxi Pharmaceuticals Corporation | Modified rnai polynucleotides and uses thereof |
| US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| WO2011119871A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Phrmaceuticals Corporation | Rna interference in ocular indications |
| EP2550002B1 (de) | 2010-03-24 | 2019-05-08 | Phio Pharmaceuticals Corp. | Rna-interferenz bei dermalen und fibrotischen erkrankungen |
| KR20160110370A (ko) | 2013-12-04 | 2016-09-21 | 알엑스아이 파마슈티칼스 코포레이션 | 화학적으로 변형된 올리고뉴클레오티드를 사용한 상처 치유의 치료 방법 |
| CN107073294A (zh) | 2014-09-05 | 2017-08-18 | 阿克赛医药公司 | 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法 |
| CA2991598A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| US11021707B2 (en) | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
| KR20230107609A (ko) * | 2020-11-12 | 2023-07-17 | 머크 샤프 앤드 돔 엘엘씨 | 항-호흡기 세포융합 바이러스 (rsv) 항체 세포-기반 역가 검정 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ244820A (en) * | 1991-10-25 | 1994-01-26 | Isis Pharmaceuticals Inc | Oligonucleotide inhibitor of epstein-barr virus. |
-
1995
- 1995-02-17 EP EP95911046A patent/EP0745090B1/de not_active Expired - Lifetime
- 1995-02-17 CA CA002181546A patent/CA2181546A1/en not_active Abandoned
- 1995-02-17 DE DE69500618T patent/DE69500618D1/de not_active Expired - Lifetime
- 1995-02-17 AT AT95911046T patent/ATE157370T1/de not_active IP Right Cessation
- 1995-02-17 AU AU18788/95A patent/AU1878895A/en not_active Abandoned
- 1995-02-17 WO PCT/US1995/002080 patent/WO1995022553A1/en active IP Right Grant
- 1995-02-17 JP JP7521953A patent/JPH09509181A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0745090A1 (de) | 1996-12-04 |
| JPH09509181A (ja) | 1997-09-16 |
| CA2181546A1 (en) | 1995-08-24 |
| ATE157370T1 (de) | 1997-09-15 |
| AU1878895A (en) | 1995-09-04 |
| EP0745090B1 (de) | 1997-08-27 |
| WO1995022553A1 (en) | 1995-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69500618D1 (de) | Oligonukleotide mit wirkung gegen das respiratorische synzytial virus | |
| TWI317735B (en) | Methods and compositions for treating hepatitis c virus | |
| BR9913935A (pt) | Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo | |
| BR9812232A (pt) | Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico | |
| NO954217L (no) | Guanosinrike antivirus-oligonukleotider | |
| WO2003051306A3 (en) | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | |
| WO2001068116A3 (en) | Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections | |
| IL143512A (en) | Azabicycloalkanes, pharmaceuticals including them and their use in the manufacture of drugs for the prevention or treatment of infection by the immunodeficiency virus | |
| WO2004039829A3 (en) | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection | |
| PL365985A1 (en) | 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions | |
| DK0662157T3 (da) | Præparater og fremgangsmåde til behandling af Hepatitis C-virus-associerede sygdomme | |
| WO2004014312A3 (en) | Small-mer compositions and methods of use | |
| WO2001032153A3 (en) | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues | |
| WO1999052515A3 (de) | Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen | |
| MY141594A (en) | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES | |
| MY144616A (en) | Substituted dihydroquinazolines | |
| ATE334670T1 (de) | Verwendung von mek-inhibitoren zur herstellung eines arzneimittels gegen negativstrang-rna-viren infektionen | |
| WO2000038660A3 (de) | Verwendung von bisphosphonaten zur prophylaxe und zur behandlung von infektiösen prozessen | |
| NO931246L (no) | Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv) | |
| ATE160354T1 (de) | Oligonukleotide mit anti-cytomegalovirus wirkung | |
| WO1997014792A3 (en) | Oligonucleotides with anti-respiratory syncytial virus activity | |
| BR0209145A (pt) | Vacina contra varìola | |
| EP0948967A3 (de) | Behandlung einer Virusinfektion bei Schweinen | |
| PT87004A (pt) | Process for the preparation of compositions for the treatment of viral infections and composites 3'-azide-2',3'-didesoxy-in osine and 3'-fluoro-2',3'-didesoxyguanosine | |
| FR2693202B1 (fr) | Polymères amphiphiles hydrosolubles, leur procédé de préparation et leur application comme épaississant. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8332 | No legal effect for de |